Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Up 6.6% – Should You Buy?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares shot up 6.6% during trading on Tuesday . The company traded as high as $26.09 and last traded at $25.81. 60,826 shares were traded during mid-day trading, a decline of 83% from the average session volume of 362,893 shares. The stock had previously closed at $24.21.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DMRA shares. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. TD Cowen started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Up 3.2%

The firm has a market capitalization of $1.54 billion, a P/E ratio of -4.48 and a beta of 1.46. The company has a 50-day moving average of $23.73 and a 200-day moving average of $25.50.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Ikarian Capital LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $6,574,000. Jain Global LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,774,000. Remedium Capital Partners LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,772,000. Boothbay Fund Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,204,000. Finally, Connective Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $100,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.